Results 111 to 120 of about 2,263 (160)

Premenstrual Syndrome and Nutritional Factors: A Narrative Review of Current Evidence and Clinical Implications. [PDF]

J Clin Med
Martire FG, Costantini E, Ianes I, d'Abate C, De Bonis M, Piccione E, Andreoli A.   +6 more
europepmc   +1 more source

Comparison of the short-term effects of dienogest and oral contraceptives on pain and quality of life in women with endometriosis: a systematic review and meta-analysis. [PDF]

BMC Womens Health
Gu Y, Shi Y, Bi B, Jiang Y, Ruan F.
europepmc   +1 more source

Efficacy of a four-drug combined regimen compared to uterine curettage in the treatment of incomplete medical abortion: a prospective observational study. [PDF]

J Health Popul Nutr
Feng Y, Zhang L.
europepmc   +1 more source

Impact of Short-Term Estrogen Therapy on Endometrial Polyps Recurrence in Women with Intrauterine Adhesion and Endometrial Polyps: A Retrospective Cohort Study. [PDF]

Int J Womens Health
Jiang S, Yi X, Zheng M, Ouyang Y, Chen Y, Xie M, Chen S, Chen D, Zhong X.   +8 more
europepmc   +1 more source

Reply to Douxfils, J.; Foidart, J.-M. Critical Considerations in the Interpretation of Bone Turnover Marker Data in HormonalContraceptive Users. Comment on "Tassi et al. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. <i>Pharmaceuticals</i> 2025, <i>18</i>, 61". [PDF]

Pharmaceuticals (Basel)
Tassi A, Londero AP, Xholli A, Lanzolla G, Bertozzi S, Savelli L, Prefumo F, Cagnacci A.   +7 more
europepmc   +1 more source

Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model. [PDF]

Int J Mol Sci
Pinto da Costa Viana D, Caseri Câmara L, Borges Palau R.   +2 more
europepmc   +1 more source

Oral Drospirenone/Estetrol as Rapid and Random Start Endometrial Preparation before Office Hysteroscopic Polypectomy: A Multicenter, Prospective, Randomized Controlled Trial.

Gynecol Obstet Invest
Etrusco A, Agrifoglio V, Chiantera V, Russo G, Golia D Apos Augè T, Monti M, Giannini A, Riemma G, Scibilia G, Pecorino B, D'Amato A, Laganà AS.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drospirenone: a novel progestin

Expert Opinion on Pharmacotherapy, 2007
Drospirenone is a novel progestin available in combined oral contraceptives and menopausal hormonal therapy. Similar to its parent compound spirolactone, an analog of spironolactone, drospirenone has antimineralocorticoid and antiandrogenic activity.
Andrea J, Rapkin, Sharon A, Winer
exaly   +3 more sources

Drospirenone/ethinyl estradiol

Drugs of Today, 2008
Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin.
Andrea J, Rapkin, Shelley N, Sorger, Sharon A, Winer   +2 more
openaire   +2 more sources

Drospirenone/ethinylestradiol

Reactions Weekly, 2021
  +4 more sources